Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Cyrta J, Rosiene J, Bareja R, Kudman S, Zoughbi WA, Motanagh S, et al. Whole-genome characterization of myoepithelial carcinomas of the soft tissue. Cold Spring Harb Mol Case Stud. 2022;8(7).

Magro CM, Mo JH, Telang G. Localized lymphomatoid papulosis: Unilesional lymphomatoid papulosis, regional lymphomatoid papulosis, and persistent agmination of lymphomatoid papulosis. Clin Dermatol. 2022;40(6):622-638.

Anderson KC, Cantley LC, Dalla-Favera R, Van Dang C, Diaz LA, DuBois RN, et al. The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Prev Res (Phila). 2022;15(11):705-712.

Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, et al. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. Clin Cancer Res. 2022;28(11):2349-2360.

Parra-Herran C, Khani F, Wobker SE. Gender distribution of editors and authors of reference textbooks in anatomic pathology: further edits are required. Mod Pathol. 2022;35(12):1784-1790.

Taylor AS, Setia N, Alpert L, Zhao L, Lamps LW, Hart J, et al. Measuring the Submucosal Depth of Invasion in Endoscopic Mucosal Resections for Barrett-associated Adenocarcinoma: Practical Issues and Relevance for the Decision for Esophagectomy. Arch Pathol Lab Med. 2022;146(11):1338-1344.

Liao D, Geyer JT, Kacker A. Cervical Lymphadenopathy in an Elderly Man. JAMA Otolaryngol Head Neck Surg. 2022;148(7):686-687.

Pagano MB, Foroutan F, Goel R, Allen ES, Cushing MM, Garcia DA, et al. Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB. Transfusion. 2022;62(8):1652-1661.

Leung W, Teater M, Durmaz C, Meydan C, Chivu AG, Chadburn A, et al. SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. Cancer Discov. 2022;12(7):1782-1803.

Tsui DC, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer. 2022;23(2):e99-e103.